CYP2E1 and risk of chemically mediated cancers

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 3, 2010, Pages 307-319

  Trafalis, Dimitrios T ^a,d   Panteli, Eleftheria S ^b,d   Grivas, Anastasios ^c,d   Tsigris, Christos ^a,d   Karamanakos, Petros N ^d  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chemically mediated cancer; CYP2E1; CYP2E1 inhibitors; Genetic polymorphism

Indexed keywords

1,3 BUTADIENE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETONE; ACRYLAMIDE; ACRYLONITRILE; ALCOHOL; ALKANE DERIVATIVE; ALKENE DERIVATIVE; ANILINE; ARSENIC; BENZENE; CARBON TETRACHLORIDE; CARCINOGEN; CHLOROFORM; CYTOCHROME P450 2E1; DIETHYLNITROSAMINE; DIMETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; HALOGENATED HYDROCARBON; HETEROCYCLIC AMINE; ISONIAZID; POLYCYCLIC AROMATIC HYDROCARBON; SOLVENT; TOBACCO SMOKE; TOLUENE; TRICHLOROETHYLENE; VINYL CHLORIDE; XENOBIOTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER RISK; CHEMICAL CARCINOGENESIS; CIGARETTE SMOKING; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; DIABETES MELLITUS; DRUG ACTIVITY; ENVIRONMENTAL FACTOR; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE ACTIVATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTOXICITY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; NONHUMAN; OBESITY; OCCUPATIONAL EXPOSURE; PHENOTYPE; RED MEAT; REVIEW; STARVATION; TOBACCO; URINARY TRACT CARCINOMA; UTERINE CERVIX CANCER;

ANIMALS; CARCINOGENS; CYTOCHROME P-450 CYP2E1; ENZYME INDUCTION; HUMANS; NEOPLASMS; XENOBIOTICS;

EID: 77249163839     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903540238     Document Type: Review

References (115)

1. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42
2. Yun CH, Miller GP, Guengerich FP. Oxidations of palkoxyacylanilides catalyzed by human cytochrome P450 1A2: structure - activity relationships and simulation of rate constants of individual steps in catalysis. Biochemistry 2001;40:4521-30
3. Klingenberg M. Pigments of rat liver microsomes. Arch Biochem Biophys 1958;75:376 •• A historical article that discovered the pigment at 450 nm.
4. Garfinkel D. Studies on pig liver microsomes. I. Enzymic and pigment composition of different microsomal fractions. Arch Biochem Biophys 1958;77:493-509
5. Omura T, Sato R. A new cytochrome in liver microsomes. J Biol Chem 1962;237:1375-6
6. Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes. II. Solubilization, purification and properties. J Biol Chem 1964;239:2379-85
7. Porter TD. Jud Coon: 35 years of P450 research, a synopsis of P450 history. Drug Metab Dispos 2004;32:1-6
8. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997;77:517-44 •• Describes in details the role of CYP2E1.
9. Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005;569:101-10
10. Lieber CS. Mechanisms of ethanol-drug nutrition interactions. Clin Toxicol 1994;32:631-81
11. Ronis MIJ, Lindros KO, Ingelman-Sundberg M. The CYP2E subfamily. In: Ioannides C, editor, Cytochromes P-450: metabolic and toxicological aspects. CRC Press, New York, 1996; p. 211-39
12. Ghanayem BI, Wang H, Sumner S. Using cytochrome P-450 gene knock-out mice to study chemical metabolism, toxicity, and carcinogenicity. Toxicol Pathol 2000;28:839-50
13. B.J. Song, Gene structure and multiple regulation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) subfamily. In: Watson RR, editor, Drug and alcohol abuse review. Alcohol and hormones. (Volume 6). Humana Press Inc., Totowa, NJ; 1995. p. 177-92
14. Johansson I, Eliasson E, Norsten C, et al. Hydroxylation of acetone by ethanoland acetone-inducible cytochrome P-450 in liver microsomes and reconstituted membranes. FEBS Lett 1986;196:59-64
15. Nakajima T, Elovaara E, Park SS, et al. Immunochemical characterization of cytochrome P-450 isozymes responsible for benzene oxidation in the rat liver. Carcinogenesis 1989;10:1713-17
16. Raucy JL, Kraner JC, Lasker JM. Bioactivation of halogenated hydrocarbons by cytochrome P4502E1. Crit Rev Toxicol 1993;23:1-20
17. Kharasch ED. Biotransformation of sevoflurane. Anesth Analg 1995;81(Suppl):S27-38
18. Garton KJ, Yuen P, Meinwald J, et al. Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metab Dispos 1995;23:1426-30
19. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993;79:795-807 • Identified the role of CYP2E1 in the metabolism of some widely used anaesthetics.
20. Peter R, Bocker R, Beaune PH, et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3:566-73
21. Tanaka E, Funae Y. Trimethadione: metabolism and assessment of hepatic drug-oxidizing capacity. Methods Enzymol 1996;272:163-9
22. Lucas D, Farez C, Bardou LG, et al. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 1998;12:553-8
23. Mandl J, Banhegyi G, Kalapos MP, et al. Increased oxidation and decreased conjugation of drugs in the liver caused by starvation. Altered metabolism of certain aromatic compounds and acetone. Chem Biol Interact 1995;96:87-101
24. McCarver DG, Byun R, Hines RN, et al. A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 1998;152:276-81
25. Bolt HM, Roos PH, Thier R. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int Arch Occup Environ Health 2003;76:174-85
26. Meskar A, Plee-Gautier E, Amet Y, et al. Alcohol-xenobiotic interactions. Role of cytochrome P450 2E1. Pathol Biol (Paris) 2001;49:696-702
27. Constan AA, Sprankle CS, Peters JM, et al. Metabolism of chloroform by cytochrome P4502E1 is required for induction of toxicity in the liver, kidney, and nose of male mice. Toxicol Appl Pharmacol 1999;160:120-6
28. Wong FW, Chan WY, Lee SS. Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol 1998;153:109-18
29. Ghanayem BI, Sanders JM, Chanas B, et al. Role of cytochrome P-450 2E1 in methacrylonitrile metabolism and disposition. J Pharmacol Exp Ther 1999;289:1054-9
30. Srumner SC, Fennell TR, Moore TA, et al. Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem Res Toxicol 1999;12:1110-16
31. Bernauer U, Vieth B, Ellrich R, et al. CYP2E1-dependent benzene toxicity: the role of extrahepatic benzene metabolism. Arch Toxicol 1999;73:189-96
32. Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res 1999;424:127-42
33. Hoffmann D, Hecht SS. Handbook of experimental pharmacology. Springer, Heidelberg; 1990
34. Rivenson A, Hoffmann D, Prokopczyk B, et al. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 1988;48:6912-7
35. Hecht SS, Hoffmann D. The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv 1989;8:273-94
36. Kang JS, Wanibuchi H, Morimura K, et al. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res 2007;7:11141-6
37. Rodriguez-Antona C, Ingelman-Sunberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006;25:1679-91
38. World Health Organization. Acrylonitrile: Environmental Health Criteria, Report 28, World Health Organization, Geneva, Switzerland, 1983
39. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P452E1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-79
40. Guengerich FP, Geiger LE, Hogy LL, et al. In vitro metabolism of acrylonitrile to 2-cyanoethylene oxide, reaction with glutathione, and irreversible binding to proteins and nucleic acids. Cancer Res 1981;41:4925-33
41. Kedderis GL, Batra R, Koop DR. Epoxidation of acrylonitrile by rat and human cytochrome P-450. Chem Res Toxicol 1993;6:866-71
42. Ghanayem BI, Sanchez IM, Burka LT. Effects of dose, strain, and dosing vehicle on methacrylonitrile disposition in ratsand identification of a novel-exhaled metabolite. Drug Metab Dispos 1992;20:643-52
43. Settels E, Bernauer U, Palavinskas R, et al. Human CYP2E1 mediates the formation of glycidamide from acrylamide. Arch Toxicol 2008;2:717-27
44. National Cancer Institute. Report on Carcinogenesis Bioassay of Chloroform. CAS No 67-66-3. Gavage Studies. National Technical Information Service No. PB264018/AS, National Institutes of Health, Bethesda, Maryland, 1976
45. Bondoc FY, Bao ZP, Hu WY, et al. Acetone catabolism by cytochrome P-450 2E1: Studies with CYP2E1-null mice. Biochem Pharmacol 1999;58:461-3
46. Brambilla G, Sciabà L, Faggin P, et al. Methylglyoxal-induced DNA-protein cross-links and cytotoxicity in Chinese hamster ovary cells. Carcinogenesis 1985;6:683-6
47. Kang JH. Oxidative damage of DNA induced by methylglyoxal in vitro. Toxicol Lett 2003;145:181-7
48. Kligerman AD, Hu Y. Some insights into the mode of action of butadiene by examining the genotoxicity of its metabolites. Chem Biol Interact 2007;166:132-9
49. Jackson TE, Schlosser PM, Medinsky MA, et al. Assessing the role of CYP2E1 in the metabolism and genotoxicity of 1,3-butadiene. Toxicol Sci 1999;48:110
50. Mendoza-Cantú A, Castorena-Torres F, Bermúdez deLeon M, et al. Occupational toluene exposure induces cytochrome p450 2e1 mrna expression in peripheral lymphocytes. Environ Health Perspect 2006;114:494-9
51. Nakajima T, Wang RS. Induction of cytochrome P450 by toluene. Int J Biochem 1994; 26:1333-40
52. Gonzalez-Jasso E, Lopez T, Lucas D, et al. CYP2E1 regulation by benzene and other small organic chemicals in rat liver and peripheral lymphocytes. Toxicol Lett 2003;144:55-67
53. Kang JH. Oxidative damage of DNA induced by methylglyoxal in vitro. Toxicol Lett 2003;145:181-7
54. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′ flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-65
55. Uematsu F, Kikuchi H, Motomiya M, et al. Association between restriction fragment length polymorphism of the human cytochrome P450 2E1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991;82:254-6
56. Watanabe J, Hayashi SI, Kawajiri K. Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. Biochem J 1994;116:321-6
57. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001;10:1239-48
58. Yoshimura K, Hanaoka T, Ohnami S, et al. Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J Hum Genet 2003;48:654-8
59. Ran L, Li-hong Y, Yue-pu P. Association of combined CYP2E1 gene polymorphism with the risk for esophageal squamous cell carcinoma in Huai'an population, China. Chin Med J 2007;120:1797-802
60. Kato S, Shields PG, Caporaso NE, et al. Cytochrome P450IIEI genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 1992;52:6712-5
61. Carriere V, Berthou F, Baird S, et al. Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996;6:203-11
62. Tsutsumi M, Takada A, Wang JS. Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology 1994;107:1430-5
63. Persson I, Johansson I, Bergling H, et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993;319:207-11
64. Parsian A, Oninger CR, Zhang ZH. Association studies of polymorphisms of CYP2E1 gene in alcoholics with cirrhosis, antisocial personality, and normal controls. Alcohol Clin Exp Res 1998;22:888-91
65. Uematsu F, Ikawa S, Kikuchi S, et al. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: Possible relevance to low smoking exposure. Pharmacogenetics 1994;4:58-63
66. Hildesheim A, Anderson LM, Chen CJ, et al. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 1997;89:1207-12
67. Wong NACS, Rae F, Simpson KJ, et al. Genetic polymorphism of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol 2000;53:88-93
68. Neuhaus T, Ko Y-D, Lorenzen K, et al. Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer. Toxicol Lett 2004;151:273-82
69. Ruwali M, Khan AJ, Shah PP, et al. Cytochrome P450 2E1 and head and neck cancer: interaction with genetic and environmental risk factors. Environ Mol Mutagen 2009;50:473-82
70. Morita M, Le Marchand L, Kono S, et al. Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Epidemiol Biomarkers Prev 2009;18:235-41
71. Kiss I, Orsos Z, Gombos K, et al. Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res 2007;27:2931-7
72. Ferreira PM, Catarino R, Pereira D, et al. Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology. Eur J Clin Pharmacol 2006;62:15-21
73. Qin JM, Yang L, Chen B, et al. Interaction of methylenetetrahydrofolate reductase C677T, cytochrome P4502E1 polymorphism and environment factors in esophageal cancer in Kazakh population. World J Gastroenterol 2008;14:6986-92
74. Guo YM, Wang Q, Liu YZ, et al. Genetic polymorphisms in cytochrome P4502E1, alcohol and aldehyde dehydrogenases and the risk of esophageal squamous cell carcinoma in Gansu Chinese males. World J Gastroenterol 2008;14:1444-9
75. Li D, Dandara C, Parker MI. Association of cytochrome P450 2E1 genetic polymorphisms with squamous cell carcinoma of the oesophagus. Clin Chem Lab Med 2005;43:370-5
76. Gao C, Takezaki T, Wu J, et al. Interaction between cytochrome p-450 2e1 polymorphisms and environmental factors with risk of esophageal and stomach cancers in Chinese. Cancer Epidemiol Biomarkers Prev 2002;11:29-34
77. Liu R, Yin LH, Pu YP. Association of combined CYP2E1 gene polymorphism with the risk for esophageal squamous cell carcinoma in Hauai'an population, China. Chin Med J 2007;120:1797-802
78. Park GT, Lee OY, Kwon SJ, et al. Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans. J Gastroenterol Hepatol 2003;18:1257-63
79. Soya SS, Vinod T, Reddy KS, et al. CYP2E1 polymorphisms and gene-environment interactions in the risk of upper aerodigestive tract cancers among Indians. Pharmacogenomics 2008;9:551-60
80. Eom SY, Zhang YW, Kim SH, et al. Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. Cancer Causes Control 2009;20:137-45
81. Liu S, Park JY, Schantz SP. Elucidation of CYP2E1 5′ regulatory RsaI/Pstl allelic variants and their role in risk for oral cancer. Oral Oncol 2001;37:437-45
82. Wang YH, Yeh SD, Shen KH, et al. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicol Appl Pharmacol 2009;241:111-8
83. Ulusoy G, Adali O, Tumer TB, et al. Significance of genetic polymorphisms at multiple loci of CYP2E1 in the risk of development of childhood acute lymphoblastic leukemia. Oncology 2007;72:125-31
84. Krajinovic M, Sinnett H, Richer C, et al. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 2002;97:230-6
85. Wang Y, Millonig G, Nair J, et al. Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology 2009;50:453-61
86. Druesne-Pecollo N, Tehard B, Mallet Y, et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol 2009;10:173-80
87. Seitz HK, Cho CH. Contribution of alcohol and tobacco use in gastrointestinal cancer development. Methods Mol Biol 2009;472:217-41
88. Koop DR. Oxidative and reductive metabolism by cytochrome P-450 2E1. FASEB J 1992;6:724-30
89. Cederbaum AI, Wu D, Mari M, et al. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic Biol Med 2001;31:1539-43
90. Bradford BU, Kono H, Isayama F, et al. Cytochrome P-450 CYP2E1, but not nicotinamide adenine dinucleotide phosphate oxidase, is required for ethanol induced oxidative DNA damage in rodent liver. Hepatology 2005;41:336-44
91. Yoo JSH, Guengerich FP, Yang CS. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 1988;48:1499-504
92. Hunt CM, Strater S, Stave EM. Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. Biochem Pharmacol 1990;10:1666-9
93. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995;57:645-55
94. Girre C, Lucas D, Hispard E, et el. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994;47:1503-8
95. O'Shea D, Davis SN, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-67
96. Dilger K, Metzler J, Bode JC, et al. CYP2E1 activity in patients with alcoholic liver disease. J Hepatol 1997;27:1009-14
97. Kharasch ED, Thummel KE, Mhyre J, et al. Single dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P4502E1. Clin Pharmacol Ther 1993;53:643-50
98. Gerhardt AC, Lucas D, Menez J-F, et al. Chlormethiazole inhibition of cytochrome P4502E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 1997;26:957-61
99. Eap CB, Schnyder C, Besson J, et al. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. Clin Pharmacol Ther 1998;64:52-7
100. Leclercq I, Desago J-P, Horsman Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 1998;64:144-19
101. Bogaards JJP, van Immen B, van Bladeren PJ. Interindividual differences in the in vitro conjugation of methylene chloride with glutathione S-transferase in 22 human liver samples. Biochem Pharmacol 1993;45:2166-9
102. Kim RB, Yamazaki H, Chiba K, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996;279:4-11
103. Le Marchand L, Wilkens LR, Kolonel LN. Ethnic differences in the lung cancer risk associated with smoking. Cancer Epidemiol Biomark Prev 1992;1:103-7
104. Le Marchand L, Kolonel LN. Cancer among Japanese migrants to Hawaii: gene-environment interactions. Rev Epidemiol Sante Publique 1992;40:425-30
105. Uematsu F, Kikuchi H, Motomiya M, et al. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn Cancer Res 1991;82:254-6
106. Wu X, Shi H, Jiang H, et al. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer. Carcinogenesis 1997;18:967-73
107. Wu XF, Amos CI, Kemp BL, et al. Cytochrome P450 2E1 DraI polymorphism in lung cancer in minority populations. Cancer Epidemiol Biomark Prev 1998;7:13-8
108. Le Marchand L, Sivaraman L, Pierce L, et al. Associations of CYP1A1, GSTM1 and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998;58:4858-63
109. Brady JF, Xiao F, Wang MH, et al. Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicol Appl Pharmacol 1991;108:366-73
110. Eneanya DI, Bianchine JR, Duran DO, et al. The actions and metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 1981;21:575-96
111. Valentine WM, Amarnath V, Amarnath K, et al. Characterization of protein adducts produced by N-methyldithiocarbamate and N-methyldithiocarbamate esters. Chem Res Toxicol 1995;8:254-61
112. Winters DK, Cederbaum AI. Time course characterization of the induction of cytochrome P-4502E1 by pyrazole and 4-methylpyrazole. Biochem Biophys Acta 1992;1117:15-24
113. Heinemann F, Assion HJ. Hepatotoxic side-effect of chlormethiazole. Pharmacopsychiatry 1996;29:196-7
114. Davenport DM, Wargovich MJ. Modulation of cytochrome P450 enzymes by organosulfur compounds from garlic. Food Chem Toxicol 2005;43:1753-62
115. Karamanakos PN, Trafalis DT, Geromichalos GD, et al. Inhibition of rat hepatic CYP2E1 by quinacrine: molecular modeling investigation and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mutagenicity. Arch Toxicol 2009;83:571-80 •• It was shown for the first time that quinacrine is a CYP2E1 inhibitor with possible antimutagenic effects against NNK.